University of California, San Francisco.
Drug Industry Document Archives.

Title: Email string – Weight gain and SERM (07/20/2001)
Document Date: 20010720
Document Type: email
Collection: Seroquel Products Liability
Bates Number: azser6992706
Exhibit Number: Dev 25
Date Added UCSF: 20100219
Page Count: 1
Description: Commercial Interference; Weight Gain; Email from Russell Giddons, Head of Global Regulatory Affairs for Seroquel, questioning why "limited" would remain as a qualifier to weight gain in the Core Data Sheet even though SERM had decided otherwise.
Company: AstraZeneca
Casename: Seroquel Products Litigation, 06-MD-01769, US District Court, Middle District of Florida
View as: PDF
Legal      Privacy      Contact Us

  UCSF Library University of California, San Francisco ©2011 The Regents of the University of California